(Reuters) – Pharmaceutical group GlaxoSmithKline Plc (GSK.L) is said to be in discussions with chipmaker Qualcomm Inc (QCOM.O) to form a joint venture as GSK looks for ways to develop medical technology, Bloomberg reported on Wednesday.
The talks are at an initial stage and nothing has been decided, people familiar with matter told Bloomberg. (bloom.bg/1UbZkSK)
GSK declined to comment, while Qualcomm was not immediately available for comments.
Earlier this month, Qualcomm said it was collaborating with Novartis AG (NOVN.VX) (NVS.N) to develop an inhaler for patients suffering from chronic obstructive pulmonary disease.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.
